Patents Assigned to Ambrx, Inc.
  • Patent number: 11311605
    Abstract: Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: April 26, 2022
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Publication number: 20220056093
    Abstract: The present invention provides methods for targeting interleukin-2 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using an interleukin-2 (IL-2) variant conjugated to a biologically active molecule that will affect cells expressing the interleukin-2 receptor.
    Type: Application
    Filed: September 11, 2019
    Publication date: February 24, 2022
    Applicant: Ambrx, Inc.
    Inventors: Sigeng CHEN, Yingchun Lu, MD Harunur Rashid, Nickolas Knudsen, Feng Tian
  • Publication number: 20220033518
    Abstract: This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are ?PSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the ?PSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.
    Type: Application
    Filed: August 26, 2020
    Publication date: February 3, 2022
    Applicant: Ambrx,Inc.
    Inventors: Richard Barnett, Feng Tian, Anna-Maria A. Hays Putnam, Marco Gymnopoulos, Nickolas Knudsen, Andrew Beck, Ying Sun
  • Publication number: 20220009986
    Abstract: The present invention provides methods for targeting interleukin-10 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using an interleukin-10 (IL-10) variant conjugated to a biologically active molecule that will affect cells expressing the interleukin-10 receptor.
    Type: Application
    Filed: October 19, 2019
    Publication date: January 13, 2022
    Applicant: Ambrx, Inc.
    Inventors: Mingchao Kang, Yingchun Lu, Nickolas Knudsen, MD Harunur Rashid, Feng Tian
  • Publication number: 20210317213
    Abstract: Described herein are novel anti-CD3 Folate antibodies and uses thereof in the treatment of diseases or conditions that would benefit from such.
    Type: Application
    Filed: August 28, 2019
    Publication date: October 14, 2021
    Applicant: Ambrx, Inc.
    Inventors: Md Harunur Rashid, Ying Sun, Feng Tian, Sung Ju Moon
  • Publication number: 20210277056
    Abstract: Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
    Type: Application
    Filed: January 5, 2021
    Publication date: September 9, 2021
    Applicant: Ambrx, Inc.
    Inventors: Zhenwei MIAO, Kyle ATKINSON, Sandra BIROC, Timothy BUSS, Melissa NEAL, Vadim KRAYNOV, Robin MARSDEN, Jason PINKSTAFF, Lillian SKIDMORE, Ying SUN, Agnieszka SZYDLIK, Delia Ianina LOPEZ DE VALENTA
  • Publication number: 20210108213
    Abstract: Disclosed herein are methods, compositions and components for optimizing or increasing expression of a protein, polypeptide or fragment therefrom.
    Type: Application
    Filed: May 1, 2019
    Publication date: April 15, 2021
    Applicant: Ambrx, Inc.
    Inventors: MD Harunur RASHID, Mark SHIMAZU, Feng Tian
  • Patent number: 10961291
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: March 30, 2021
    Assignee: AMBRX, INC.
    Inventors: Thomas P. Cujec, Roberto Mariani, Anna-Maria A. Hays Putnam, William M. Keefe, Nick Knudsen, Lillian Skidmore, Jason Pinkstaff, Vadim Kraynov
  • Patent number: 10960080
    Abstract: Disclosed herein are porcine interferon alpha variants (pIFN-?) comprising a synthetic amino acid at select locations in pIFN-? and a one or two amino acid insertion in the N-terminus after removal of the signal peptide. The pIFN-? variants can further be pegylated. Methods of making and administering these compounds to treat virus infections in pigs and formulations comprising the variants are also provided.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: March 30, 2021
    Assignees: Elanco US Inc., Ambrx, Inc.
    Inventors: Peter Connor Canning, Nickolas Knudsen, Lillian Skidmore
  • Patent number: 10954270
    Abstract: Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: March 23, 2021
    Assignee: Ambrx, Inc.
    Inventors: Zhenwei Miao, Kyle Atkinson, Sandra Biroc, Timothy Buss, Melissa Neal, Vadim Kraynov, Robin Marsden, Jason Pinkstaff, Lillian Skidmore, Ying Sun, Agnieszka Szydlik, Delia Ianina Lopez De Valenta
  • Publication number: 20210054039
    Abstract: The present invention relates to variants of porcine granulocyte colony stimulating factor (pG-CSF). The pG-CSF variants are useful in treating preventing or reducing the incidence of bacterial infections in swine. Methods of treating swine are disclosed.
    Type: Application
    Filed: October 10, 2018
    Publication date: February 25, 2021
    Applicants: Elanco US Inc., Ambrx, Inc.
    Inventors: Peter Connor CANNING, Nickolas KNUDSEN, Md Harunur RASHID
  • Publication number: 20210017527
    Abstract: Disclosed herein are methods and compositions for generation of cell lines to promote unnatural amino acid-containing protein production using genome engineering technology.
    Type: Application
    Filed: June 2, 2018
    Publication date: January 21, 2021
    Applicant: Ambrx, Inc.
    Inventors: Sigeng Chen, Yingchun LU, Feng TIAN
  • Publication number: 20210015940
    Abstract: The invention relates to prostate specific membrane antigen humanized antibodies (anti-PSMA) and anti-PSMA antibody drug conjugates. The invention also relates to methods and compositions for using anti-PSMA antibody drug conjugates in inhibiting, preventing or treating PSMA related diseases or cancers.
    Type: Application
    Filed: March 29, 2019
    Publication date: January 21, 2021
    Applicant: Ambrx, Inc.
    Inventors: Shivarupam Bhowmik, Jianing Wang, Jinming Xia, William Brady, Feng Tian
  • Publication number: 20200392197
    Abstract: Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
    Type: Application
    Filed: August 27, 2020
    Publication date: December 17, 2020
    Applicants: Merck Sharp & Dohme Corp., Ambrx, Inc.
    Inventors: Paul E. Carrington, Grigori Ermakov, Robert M. Garbaccio, Wolfgang Seghezzi, Elisabetta Bianchi, Federica Orvieto, Dennis Gately, Nick Knudsen, Anthony Manibusan
  • Patent number: 10800856
    Abstract: This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are ?PSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the ?PSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: October 13, 2020
    Assignee: Ambrx, Inc.
    Inventors: Richard S. Barnett, Feng Tian, Anna-Maria A. Hays Putnam, Marco Gymnopoulos, Nick Knudsen, Andrew Beck, Ying Sun
  • Patent number: 10751391
    Abstract: Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: August 25, 2020
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Patent number: 10702588
    Abstract: Modified relaxin polypeptides and their uses thereof are provided.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: July 7, 2020
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Patent number: 10550190
    Abstract: Phosphate-based linkers with tunable stability for intracellular delivery of drug conjugates are described. The phosphate-based linkers comprise a monophosphate, diphosphate, triphosphate, or tetraphosphate group (phosphate group) and a linker arm comprising a tuning element and optionally a spacer. A payload is covalently linked to the phosphate group at the distal end of the linker arm and the functional group at the proximal end of the linker arm is covalently linked to a cell-specific targeting ligand such as an antibody. These phosphate-based linkers have a differentiated and tunable stability in blood vs. an intracellular environment (e.g. lysosomal compartment).
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: February 4, 2020
    Assignees: Merck Sharp & Dohme Corp., Ambrx, Inc.
    Inventors: Robert M. Garbaccio, Jeffrey Kern, Philip E. Brandish, Sanjiv Shah, Linda Liang, Ying Sun, Jianing Wang, Nick Knudsen, Andrew Beck, Anthony Manibusan, Dennis Gately
  • Publication number: 20190338039
    Abstract: This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are ?CD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the ?CD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.
    Type: Application
    Filed: December 18, 2018
    Publication date: November 7, 2019
    Applicant: Ambrx, Inc.
    Inventors: Richard S. Barnett, Nick Knudsen, Ying Sun, Sandra Biroc, Timothy Buss, Tsotne Javahishvili, Damien Bresson, Shailaja Srinagesh, Amha Hewet, Jason Pinkstaff
  • Patent number: 10428333
    Abstract: Compositions and methods of producing vaccines, including methods wherein whole organism vaccines are provided with limited replication abilities, thereby increasing vaccine safety and efficacy, through the use of non-natural, unnatural, or non-naturally encoded amino acids.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: October 1, 2019
    Assignee: Ambrx Inc.
    Inventors: Feng Tian, Brad Hehli